Figma Shares Indicated To Open $105/$110
Amicus Therapeutics , Inc. (NASDAQ:FOLD) stock has reached a 52-week low, touching down at $6.99. InvestingPro analysis indicates the stock is currently in oversold territory, with analyst price targets ranging from $12 to $21. This latest price movement reflects a significant downturn for the biotechnology company, which specializes in therapies for rare and orphan diseases. While the stock has declined 40.04% over the past year, the company maintains impressive fundamentals with a 90% gross profit margin and 32% revenue growth. According to InvestingPro's comprehensive analysis, which includes 13 additional key insights available to subscribers, the stock appears undervalued at current levels. The 52-week low serves as a critical marker for the stock, which has struggled amidst a competitive market and shifting investor sentiments. Despite current challenges, the company maintains strong liquidity with a current ratio of 3.39, and analysts expect positive net income growth this year. As stakeholders and analysts observe the company's performance, the 1-year change data underscores the need for strategic initiatives to revitalize Amicus Therapeutics' market position and restore confidence in its growth potential.
In other recent news, Amicus Therapeutics reported a full-year 2024 total revenue of $528.3 million, marking a 33% increase from the previous year. Sales of its leading product, Galafold, reached $458.2 million, showing a 19% growth, while Pombiliti+Opfolda contributed $70.2 million. BofA Securities adjusted its price target for Amicus Therapeutics to $14, maintaining a Buy rating, reflecting confidence in the company's future prospects. Goldman Sachs also reiterated a Neutral rating with a $14 price target, noting the company's revenue aligned with expectations. Amicus Therapeutics has forecasted Galafold revenue to grow by 10%-15% in 2025, with Pombiliti+Opfolda expected to increase by 65%-85%.
Additionally, Amicus Therapeutics filed a prospectus supplement for the sale of unsold shares under its at-the-market program. The legal opinion confirming the legality of the shares was provided by Troutman Pepper Locke LLP. Jefferies analysts, maintaining a Buy rating with an $18 price target, noted the company's conservative outlook on Pompe disease treatments, suggesting potential for consistent performance improvements. The company anticipates achieving positive GAAP net income in the second half of 2024, signaling a positive outlook for its financial health.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.